33,580 Shares in Bristol Myers Squibb Company $BMY Acquired by one8zero8 LLC

Key Points

• one8zero8 LLC acquired 33,580 Bristol Myers Squibb shares in the second quarter, valued at approximately $1.94 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company maintained fiscal 2026 EPS guidance of $6.75–$7.00.
• BMY recently traded at $67.59 and pays a quarterly dividend of $0.63, equivalent to a 3.7% annual yield. Analysts’ consensus rating is “Moderate Buy”, with an average price target of $66.06.

one8zero8 LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 33,580 shares of the biopharmaceutical company's stock, valued at approximately $1,935,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb in the fourth quarter worth $25,000. Physician Wealth Advisors Inc. lifted its holdings in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 202 shares during the period. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the second quarter worth about $25,000. Addison Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $32,000. Finally, Bayban bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $31,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Up 2.3%

NYSE BMY opened at $67.59 on Thursday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $138.06 billion, a P/E ratio of 14.89, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The stock's 50-day moving average price is $60.18 and its 200-day moving average price is $59.24.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the previous year, the company posted $1.46 EPS. The firm's revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.7%. Bristol Myers Squibb's dividend payout ratio is 55.51%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BMY. JPMorgan Chase & Co. increased their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Jefferies Financial Group lowered shares of Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research report on Wednesday, August 5th. Citigroup reiterated a "neutral" rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Roth Capital began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating and a $75.00 price target on the stock. Finally, BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source